Key Highlights
- The former chief executive stepped down on June 17, 2026; Jack Fraser now serves as interim CEO.
- The severance agreement provides $200,000 cash, with a prorated $4,615.38 payable on the July 15, 2026 payroll.
- Unvested options covering 64,583 shares at $0.07 per share will vest immediately, with a 90‑day exercise period.
- Share sale limits cap daily volume at 2,500 shares and enforce a minimum price of $0.45 per share.
Aspira Women's Health Inc. (NASDAQ: AWHL) disclosed that its chief executive vacated the position on June 17, 2026. To maintain operational continuity, the board promptly appointed Jack Fraser as interim chief executive, tasking him with overseeing day‑to‑day activities while a search for a permanent successor proceeds.
Leadership Transition
The board’s decision to elevate Jack Fraser to interim CEO underscores a focus on steady governance during an executive change. Fraser assumes full authority over corporate functions, and the board will evaluate candidates for the long‑term role.
Severance Terms
Under the separation arrangement, the departing executive will receive a total cash severance of $200,000, disbursed through normal payroll channels. A prorated amount of $4,615.38 is scheduled for the July 15, 2026 payroll run. The agreement also contains standard confidentiality and release provisions.
Equity Vesting
The settlement accelerates the vesting of previously unvested options for 64,583 shares of common stock, each with an exercise price of $0.07. Those options become exercisable as of the effective date, and the former executive has a ninety‑day window to exercise them. All other unvested equity awards are terminated as of the separation date.
Benefit Continuation
Aspira Women’s Health will continue to subsidize COBRA premiums for the former executive and eligible dependents for six months following the separation, unless alternative coverage is secured. This extension helps preserve health benefits during the transition.
Share Sale Restrictions
Shares acquired through the exercised options are subject to a 90‑day lock‑up per exercise. After the lock‑up, daily sales may not exceed 2,500 shares, and no transaction may be executed below a $0.45 price floor. All sales must be routed through a broker‑dealer approved by Aspira Women’s Health and reported to the acting chief executive prior to execution.
Regulatory Filing
A copy of the separation agreement, together with the related equity award provisions, is attached to the company’s filing with the SEC (EXCHANGE COMMISSION Washington, D.C. 20549) and is referenced.
Industry Context
Leadership changes in the women’s health sector can influence investor sentiment, particularly when they involve sizable severance packages and accelerated equity vesting. Companies often balance the need to retain talent with the imperative to align compensation structures with market benchmarks. In this case, the stipulated daily volume limit and price floor are typical mechanisms used to mitigate market impact when insiders sell shares.
Outlook for Stakeholders
The transition to interim leadership, combined with the disclosed severance and equity terms, is intended to minimize disruption to operations and financial performance. Investors will monitor how the interim CEO navigates ongoing initiatives and will await further communication regarding the appointment of a permanent chief executive.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...